Walleye Capital
BCRX icon

Walleye Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Walleye Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.9K Sell
2,300
-36,500
-94% -$283K ﹤0.01% 4066
2025
Q4 		$303K Buy
+38,800
New +$280K ﹤0.01% 3309
2025
Q3 		– Sell
-8,300
Closed -$74.4K – 4496
2025
Q2 		$74.4K Buy
+8,300
New +$77.3K ﹤0.01% 3905
2024
Q4 		– Sell
-1,400
Closed -$10.6K – 4861
2024
Q3 		$10.6K Buy
+1,400
New +$10.6K ﹤0.01% 4904
2024
Q2 		– Sell
-24,800
Closed -$126K – 5588
2024
Q1 		$126K Sell
24,800
-31,100
-56% -$175K ﹤0.01% 4264
2023
Q4 		$335K Sell
55,900
-14,200
-20% -$82.3K ﹤0.01% 3285
2023
Q3 		$496K Buy
70,100
+54,500
+349% +$392K ﹤0.01% 2827
2023
Q2 		$110K Buy
15,600
+3,000
+24% +$24.1K ﹤0.01% 3390
2023
Q1 		$105K Sell
12,600
-24,200
-66% -$233K ﹤0.01% 2901
2022
Q4 		$422K Sell
36,800
-16,800
-31% -$210K 0.01% 1559
2022
Q3 		$675K Buy
+53,600
New +$690K 0.01% 1238

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Walleye Capital's BCRX Position: Q1 2026 in Review

Walleye Capital reduced its BioCryst Pharmaceuticals (BCRX) stake by 89% in Q1 2026, selling an estimated $1.75M and leaving 26,793 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #3178.

Walleye Capital first reported a position in BCRX in Q4 2019 and has held it in 21 quarters since. The position peaked at $20.6M in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Walleye Capital held 26,793 shares of BioCryst Pharmaceuticals worth $255K as of Q1 2026.
  • Walleye Capital sold 224,877 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $1.75M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3178 holding.
  • Walleye Capital first reported a position in BioCryst Pharmaceuticals in Q4 2019 and has held it in 21 quarters since.
  • Walleye Capital's BioCryst Pharmaceuticals position peaked at $20.6M in Q2 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.